279 related articles for article (PubMed ID: 31978184)
1. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.
Aguilera-Diaz A; Vazquez I; Ariceta B; Mañú A; Blasco-Iturri Z; Palomino-Echeverría S; Larrayoz MJ; García-Sanz R; Prieto-Conde MI; Del Carmen Chillón M; Alfonso-Pierola A; Prosper F; Fernandez-Mercado M; Calasanz MJ
PLoS One; 2020; 15(1):e0227986. PubMed ID: 31978184
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms.
Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Jones K; Ahluwalia M; Okechukwu N; Savage NM; Kota V; Rojiani AM; Kolhe R
PLoS One; 2020; 15(10):e0240976. PubMed ID: 33075099
[TBL] [Abstract][Full Text] [Related]
3. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
[TBL] [Abstract][Full Text] [Related]
4. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
5. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
6. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics.
Alonso CM; Llop M; Sargas C; Pedrola L; Panadero J; Hervás D; Cervera J; Such E; Ibáñez M; Ayala R; Martínez-López J; Onecha E; de Juan I; Palanca S; Martínez-Cuadrón D; Rodríguez-Veiga R; Boluda B; Montesinos P; Sanz G; Sanz MA; Barragán E
J Mol Diagn; 2019 Mar; 21(2):228-240. PubMed ID: 30576870
[TBL] [Abstract][Full Text] [Related]
8. Coverage analysis in a targeted amplicon-based next-generation sequencing panel for myeloid neoplasms.
Yan B; Hu Y; Ng C; Ban KH; Tan TW; Huan PT; Lee PL; Chiu L; Seah E; Ng CH; Koay ES; Chng WJ
J Clin Pathol; 2016 Sep; 69(9):801-4. PubMed ID: 26896490
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of custom-designed NGS panel testing in pediatric tumors.
Surrey LF; MacFarland SP; Chang F; Cao K; Rathi KS; Akgumus GT; Gallo D; Lin F; Gleason A; Raman P; Aplenc R; Bagatell R; Minturn J; Mosse Y; Santi M; Tasian SK; Waanders AJ; Sarmady M; Maris JM; Hunger SP; Li MM
Genome Med; 2019 May; 11(1):32. PubMed ID: 31133068
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
[TBL] [Abstract][Full Text] [Related]
11. MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.
Poirot B; Doucet L; Benhenda S; Champ J; Meignin V; Lehmann-Che J
J Thorac Oncol; 2017 Oct; 12(10):1582-1587. PubMed ID: 28779874
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing-based panel testing for myeloid neoplasms.
Kuo FC; Dong F
Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
[TBL] [Abstract][Full Text] [Related]
13. Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid Malignancies.
Alkhatabi HA; Alqahtani W; Alsolami R; Elaimi A; Hazzazi MS; Almashjary MN; Alkhatabi HA; Alghuthami ME; Daous YM; Yasin EB; Barefah A
Int J Gen Med; 2024; 17():37-48. PubMed ID: 38204493
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
15. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.
Carbonell D; Suárez-González J; Chicano M; Andrés-Zayas C; Triviño JC; Rodríguez-Macías G; Bastos-Oreiro M; Font P; Ballesteros M; Muñiz P; Balsalobre P; Kwon M; Anguita J; Díez-Martín JL; Buño I; Martínez-Laperche C
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540291
[TBL] [Abstract][Full Text] [Related]
17. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.
Spencer DH; Abel HJ; Lockwood CM; Payton JE; Szankasi P; Kelley TW; Kulkarni S; Pfeifer JD; Duncavage EJ
J Mol Diagn; 2013 Jan; 15(1):81-93. PubMed ID: 23159595
[TBL] [Abstract][Full Text] [Related]
18. Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis.
Schejbel L; Novotny GW; Breinholt MF; El Fassi D; Schöllkopf C; Hogdall E; Nørgaard P
Mol Diagn Ther; 2021 Mar; 25(2):251-266. PubMed ID: 33687704
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of Targeted Next-Generation Sequencing Panels for Detection of Germline Variants in Inherited Diseases.
Santani A; Murrell J; Funke B; Yu Z; Hegde M; Mao R; Ferreira-Gonzalez A; Voelkerding KV; Weck KE
Arch Pathol Lab Med; 2017 Jun; 141(6):787-797. PubMed ID: 28322587
[TBL] [Abstract][Full Text] [Related]
20. Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.
LaDuca H; Farwell KD; Vuong H; Lu HM; Mu W; Shahmirzadi L; Tang S; Chen J; Bhide S; Chao EC
PLoS One; 2017; 12(2):e0170843. PubMed ID: 28152038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
